Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 362 clinical trials
Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

The purpose of this Phase 3 study is to determine whether iptacopan is efficacious and safe for the treatment of PNH patients who are naive to complement inhibitor therapy

vaccination
flow cytometry
complement inhibitor
neisseria meningitidis
haemophilus influenzae
  • 0 views
  • 20 Sep, 2021
  • 5 locations
Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

This is an evaluation of the effectiveness of darbepoetin alpha in treating anemia of MDS patients with an International Prognostic Scoring System (IPSS) score of low or intermediate 1.

blood transfusion
refractory cytopenia with multilineage dysplasia
darbepoetin alfa
chronic myelomonocytic leukemia
anemia
  • 33 views
  • 07 Nov, 2020
  • 23 locations
Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)

The purpose of this study is to determine if AR-67 is effective in the treatment for patients with MDS.

hydroxyurea
myelomonocytic leukemia
leukemia
chronic myelomonocytic leukemia
azacitidine
  • 30 views
  • 08 Nov, 2020
  • 1 location
APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Phase 1 study evaluating the safety and efficacy of APR-548 in combination with Azacitidine for the treatment of TP53-Mutant Myelodysplastic Syndromes.

  • 0 views
  • 05 May, 2021
  • 3 locations
A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

The main purpose of this study are to determine the recommended Phase 2 dose(s) (RP2D) route of administration, schedule and the maximum tolerated dose (MTD) in Part 1 and to determine the safety and tolerability of JNJ-67571244 at the RP2D regimen(s) and to evaluate the preliminary clinical activity of JNJ-67571244 …

refractory acute myeloid leukemia (aml)
neoadjuvant therapy
leukemia
direct bilirubin
gilbert's syndrome
  • 66 views
  • 15 Sep, 2021
  • 26 locations
T-cell Depleted Donor Lymphocyte Infusion (DLI)for Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

Primary Objectives: This a pilot project to determine the feasibility of the preemptive CD8+ depleted T-cell donor lymphocyte infusion (DLI) in: - Reducing the incidence of graft versus host disease (GVHD) based on standard classification of acute and chronic GVHD - Improving hte disease remission rate in comparison with our …

high risk myelodysplastic syndrome
leukemia
bone marrow procedure
serum bilirubin level
donor lymphocyte infusion
  • 35 views
  • 07 Nov, 2020
  • 1 location
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

This phase I/2 trial studies the side effects and best dose of activated natural killer cells in treating patients with relapsed or refractory acute myeloid leukemia and myeloid dysplastic syndromes. Giving chemotherapy before a donor natural killer cell infusion helps stop the growth of cancer cells. It may also stop …

refractory acute myeloid leukemia (aml)
blast cells
lenalidomide
fludarabine
cell transplantation
  • 79 views
  • 27 May, 2021
  • 1 location
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

This study will assess the safety and preliminary efficacy of escalating doses of SHR-1702 monotherapy in relapsed/refractory AML and intermediate-high risk MDS

  • 0 views
  • 27 Mar, 2021
  • 1 location
IFN- to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

myelodysplastic syndrome (MDS) after alloSCT with no active or history of III-IV acute graft-versus-host disease (GVHD). It is hypothesized that IFN- will promote graft-vs-leukemia (GVL) in patients with AML/MDS

  • 0 views
  • 22 Apr, 2021
  • 2 locations
Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents

Patients with low-risk MDS verifying the eligibility criteria may be included in the study.

cmml-1
myelomonocytic leukemia
deferasirox
leukemia
anemia
  • 3 views
  • 24 Jan, 2021
  • 1 location